2020 ANNUAL REPORT
Duke & Deerfield Announce Four Points Innovation
Duke University and Deerfield Management Company, a healthcare investment firm, announced the creation of a major translational research collaboration. The alliance is expected to accelerate the preclinical development of new drugs for improved quality of life and cures for disease.
NEW START-UP: Tellus Therapeutics
Tellus is developing novel small molecules derived from human maternal breast milk for the treatment of newborns with perinatal brain injury. Tellus’ lead candidate, TT-20, induces regeneration of myelin-producing oligodendrocytes, reverses white matter injury in animal models of perinatal brain injury and multiple sclerosis, and is pursuing a novel regulatory path to evaluate safety and efficacy in newborns with brain injury.
VielaBio Announces U.S. FDA Approval of UPLIZNA™
Viela Bio has been approved for a drug to treat adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-AQP4 antibody-positive.
17
NEW START-UPS CREATED
This year we’ve helped grow and develop ventures ranging from disease-resistant crops to mindfulness tools.
3D-Printing Gives Medical Teams COVID Protection
COVID-19 Engineering Response Team tackles powered, air-purifying respirator (PAPR)
NEW START-UP:
Upstream Biotechnology
Developing broad-spectrum disease-resistant crops to eliminate pesticide use, reduce production costs, and increase crop yield
NEW START-UP:
Tumult Labs
Algorithm and software platform that systematically de-identifies data such that original data cannot be reconstructed